

4basebio plc

(â€œ4basebioâ€ or the "Company")
Â

Directorâ€™s Dealing

3 March 2025 â€“ 4basebio PLC (AIM: 4BB), which develops and commercialises the large-scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, announces that it was informed on 28 February 2025 by Dr. Amy Walker, COO of the Company, that on the same day, she acquired ordinary shares in the Company through the market, at a price of 1,120p as follows:Â

Name	Number of Shares Acquired	Shareholding Prior to the Acquisition	Shareholding Following the Acquisition	Enlarged Shareholding as a Percentage of Issued Share Capital
Dr. Amy Walker	1,151	42,865*	44,016	0.28%

* Dr Walkerâ€™s shareholding includes 2,818 ordinary shares that had been omitted in the announcement of 8 August 2024

The issued share capital of the Company comprises 15,477,395 ordinary shares.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310.

Enquiries

4basebio PLC	+44 (0)1223 967 943
Dr. Heikki Lanckriet Nominated Adviser	+44 (0)20 7213 0880

Cairn Financial Advisers LLP

Jo Turner / Sandy Jamieson / Ed Downes Joint Corporate Broker	+44 (0)20 7653 4000
--	---------------------

RBC Capital Markets

Rupert Walford / Kathryn Deegan Joint Corporate Broker	+44 (0)20 7220 0500
---	---------------------

Cavendish Capital Markets Limited

Geoff Nash / Nigel Birks

Notes to Editors**About 4basebio**

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Companyâ€™s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1	Details of the person discharging managerial responsibilities/person closely associated	
a.	Name	Amy Walker
2	Reason for notification	
a.	Position/Status	COO
b.	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	

a.	Name	4basebio plc	
b.	LEI	213800E2DX9EAIUNCB30	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares ISIN: GB00BMCLYF79	
b.	Nature of the transaction	Acquisition of ordinary shares	
		Price(s) per share (p)	Volume(s)
		1,120p	1,151
d.	Aggregated information • Volume • Price	<ul style="list-style-type: none"> • 1,151 • 1,120 pence per share 	
e.	Date of the transaction	28/02/2025	
f.	Place of the transaction	London Stock Exchange, AIM	